Treatment of Neurocysticercosis (NCC)
Treatment of NCC must be tailored to the specific form of disease, with the critical first step being assessment for elevated intracranial pressure—if hydrocephalus or diffuse cerebral edema is present, manage this surgically or with corticosteroids alone and do NOT give antiparasitic drugs until resolved 1.
Pre-Treatment Evaluation
Before initiating therapy, complete these essential steps:
- Fundoscopic examination (mandatory to rule out ocular cysticercosis before antiparasitics) 1
- Screen for latent tuberculosis if prolonged corticosteroids anticipated 1
- Screen or empirically treat for Strongyloides stercoralis if prolonged corticosteroids anticipated 1
- Obtain both MRI and CT imaging to fully characterize lesion burden and type 1
Treatment Algorithm by Disease Form
Viable Parenchymal Neurocysticercosis (VPN)
The treatment depends critically on lesion number:
For 1-2 viable parenchymal cysts:
- Albendazole monotherapy: 15 mg/kg/day (maximum 1200 mg/day) divided twice daily for 10-14 days with food 1
- This is superior to no treatment and preferred over combination therapy for limited disease 1
For >2 viable parenchymal cysts:
- Combination therapy: Albendazole 15 mg/kg/day PLUS praziquantel 50 mg/kg/day for 10-14 days 1
- This combination is superior to albendazole monotherapy for multiple lesions 1
Persistent lesions at 6 months: Consider retreatment with antiparasitic therapy 1
Single Enhancing Lesions (SELs) with Seizures
Triple therapy is recommended:
- Antiepileptic drugs (choice based on availability, cost, and side effects) 1
- Albendazole 15 mg/kg/day in twice-daily doses for 1-2 weeks with meals 1
- Corticosteroids initiated BEFORE starting antiparasitic therapy 1
The corticosteroids must be started first to prevent inflammatory complications from parasite death 1.
Antiepileptic drug discontinuation: After 6 months seizure-free, taper and stop AEDs if the lesion has resolved AND the patient lacks risk factors (residual cysts, calcifications, breakthrough seizures, or >2 total seizures) 1
Calcified Parenchymal Neurocysticercosis (CPN)
Symptomatic therapy ONLY—do NOT use antiparasitic drugs 1. Calcified lesions represent dead parasites and antiparasitics provide no benefit 1.
- Treat seizures with antiepileptic drugs
- Do NOT routinely use corticosteroids for perilesional edema in isolated CPN 1
- For refractory epilepsy, consider surgical evaluation for seizure focus removal 1
Intraventricular Neurocysticercosis (IVN)
Surgical removal is preferred when technically feasible:
- For fourth ventricular cysts: surgical removal over medical therapy or shunt alone 1
- For adherent/difficult cysts: shunt surgery for hydrocephalus rather than risky cyst removal 1
Perioperative management:
- Corticosteroids to decrease brain edema 1
- Consider antiparasitic drugs with corticosteroids following shunt insertion 1
Subarachnoid Neurocysticercosis
This form often requires prolonged courses of antiparasitic and anti-inflammatory treatment 2. Specific duration and dosing should be guided by imaging response.
Monitoring During Treatment
For albendazole >14 days:
- Monitor for hepatotoxicity and leukopenia 1
For combination albendazole + praziquantel:
- No additional monitoring beyond that for albendazole monotherapy 1
Follow-Up Imaging
- Repeat MRI at least every 6 months until resolution of cystic lesions for both VPN and SELs 1
Critical Pitfalls to Avoid
Never give antiparasitic drugs to patients with untreated hydrocephalus or diffuse cerebral edema—this can be fatal 1. Manage elevated intracranial pressure first.
Always start corticosteroids BEFORE antiparasitic therapy in SELs to prevent severe inflammatory reactions 1
Do not skip fundoscopic examination—ocular cysticercosis is a contraindication to antiparasitic therapy due to risk of blindness 1
Do not treat calcified lesions with antiparasitic drugs—they are dead parasites and treatment provides no benefit 1
Be aware that drug interactions reduce praziquantel levels: carbamazepine, phenytoin, and dexamethasone significantly decrease praziquantel bioavailability 3
The 2017 IDSA/ASTMH guidelines 1 represent the most authoritative and recent evidence-based recommendations for NCC management, with strong evidence supporting antiparasitic therapy for viable parenchymal disease to improve both radiologic resolution and seizure outcomes.